company background image
B8F

Biofrontera XTRA:B8F Stock Report

Last Price

€1.06

Market Cap

€60.1m

7D

2.4%

1Y

-60.7%

Updated

22 May, 2022

Data

Company Financials +
B8F fundamental analysis
Snowflake Score
Valuation6/6
Future Growth3/6
Past Performance3/6
Financial Health4/6
Dividends0/6

B8F Stock Overview

Biofrontera AG, a biopharmaceutical company, engages in the research, development, and marketing of dermatological products.

Biofrontera Competitors

 

 

 

 

 

 

 

 

 

 

 

 

Price History & Performance

Summary of all time highs, changes and price drops for Biofrontera
Historical stock prices
Current Share Price€1.06
52 Week High€3.17
52 Week Low€0.96
Beta1.54
1 Month Change-9.79%
3 Month Change-27.15%
1 Year Change-60.74%
3 Year Change-85.20%
5 Year Change-74.28%
Change since IPO-93.09%

Recent News & Updates

Shareholder Returns

B8FDE PharmaceuticalsDE Market
7D2.4%5.6%-0.09%
1Y-60.7%14.2%-12.9%

Return vs Industry: B8F underperformed the German Pharmaceuticals industry which returned 14.2% over the past year.

Return vs Market: B8F underperformed the German Market which returned -12.9% over the past year.

Price Volatility

Is B8F's price volatile compared to industry and market?
B8F volatility
B8F Average Weekly Movement9.0%
Pharmaceuticals Industry Average Movement6.8%
Market Average Movement6.3%
10% most volatile stocks in DE Market10.6%
10% least volatile stocks in DE Market3.5%

Stable Share Price: B8F is more volatile than 75% of German stocks over the past 3 months, typically moving +/- 9% a week.

Volatility Over Time: B8F's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of German stocks.

About the Company

FoundedEmployeesCEOWebsite
199799Hermann Lubberthttps://www.biofrontera.com

Biofrontera AG, a biopharmaceutical company, engages in the research, development, and marketing of dermatological products. Its products include Ameluz and BF-RhodoLED lamp for the treatment of mild and moderate actinic keratoses on the face and scalp, field cancerization, and fatal squamous cell carcinoma. The company also develops RhodoLED XL for the treatment of multiple interspersed lesions; Belixos, a modern active cosmetic product for irritated and sensitive skin; and Xepi for the treatment of antibiotic-resistant bacteria.

Biofrontera Fundamentals Summary

How do Biofrontera's earnings and revenue compare to its market cap?
B8F fundamental statistics
Market Cap€60.12m
Earnings (TTM)€15.10m
Revenue (TTM)€29.87m

4.0x

P/E Ratio

2.0x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
B8F income statement (TTM)
Revenue€29.87m
Cost of Revenue€4.12m
Gross Profit€25.75m
Other Expenses€10.66m
Earnings€15.10m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)0.27
Gross Margin86.20%
Net Profit Margin50.53%
Debt/Equity Ratio1.7%

How did B8F perform over the long term?

See historical performance and comparison

Valuation

Is Biofrontera undervalued compared to its fair value and its price relative to the market?

Valuation Score

6/6

Valuation Score 6/6

  • Below Fair Value

  • Significantly Below Fair Value

  • PE vs Industry

  • PE vs Market

  • PEG Ratio

  • PB vs Industry


>50%

Undervalued compared to fair value

Share Price vs. Fair Value

Below Fair Value: B8F (€1.06) is trading below our estimate of fair value (€4.18)

Significantly Below Fair Value: B8F is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: B8F is good value based on its PE Ratio (4x) compared to the German Pharmaceuticals industry average (23.5x).

PE vs Market: B8F is good value based on its PE Ratio (4x) compared to the German market (17.2x).


Price to Earnings Growth Ratio

PEG Ratio: B8F is good value based on its PEG Ratio (0.2x)


Price to Book Ratio

PB vs Industry: B8F is good value based on its PB Ratio (2x) compared to the DE Pharmaceuticals industry average (2.6x).


Future Growth

How is Biofrontera forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

Future Growth Score

3/6

Future Growth Score 3/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


16.5%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: B8F's forecast earnings growth (16.5% per year) is above the savings rate (-0.05%).

Earnings vs Market: B8F's earnings (16.5% per year) are forecast to grow faster than the German market (7.6% per year).

High Growth Earnings: B8F's earnings are forecast to grow, but not significantly.

Revenue vs Market: B8F's revenue (19.3% per year) is forecast to grow faster than the German market (4.7% per year).

High Growth Revenue: B8F's revenue (19.3% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if B8F's Return on Equity is forecast to be high in 3 years time


Past Performance

How has Biofrontera performed over the past 5 years?

Past Performance Score

3/6

Past Performance Score 3/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


27.3%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: B8F has a large one-off gain of €39.7M impacting its March 31 2022 financial results.

Growing Profit Margin: B8F became profitable in the past.


Past Earnings Growth Analysis

Earnings Trend: B8F has become profitable over the past 5 years, growing earnings by 27.3% per year.

Accelerating Growth: B8F has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: B8F has become profitable in the last year, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (14.9%).


Return on Equity

High ROE: B8F's Return on Equity (35.6%) is considered high.


Financial Health

How is Biofrontera's financial position?

Financial Health Score

4/6

Financial Health Score 4/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Debt Coverage

  • Interest Coverage

Financial Position Analysis

Short Term Liabilities: B8F's short term assets (€12.0M) do not cover its short term liabilities (€14.0M).

Long Term Liabilities: B8F's short term assets (€12.0M) exceed its long term liabilities (€1.1M).


Debt to Equity History and Analysis

Debt Level: B8F has more cash than its total debt.

Reducing Debt: B8F's debt to equity ratio has reduced from 68.4% to 1.7% over the past 5 years.

Debt Coverage: B8F's debt is well covered by operating cash flow (6112.2%).

Interest Coverage: Insufficient data to determine if B8F's interest payments on its debt are well covered by EBIT.


Balance Sheet


Dividend

What is Biofrontera current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate B8F's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate B8F's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if B8F's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if B8F's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as B8F has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

3.2yrs

Average management tenure


CEO

Hermann Lubbert (65 yo)

25.33yrs

Tenure

€621,000

Compensation

Dr. Prof. Hermann Lubbert, Ph.D. is a Co-Founder of Biofrontera AG and serves as its Chief Executive Officer since 1997 and served as its Chairman of Management Board since 2000 until December 13, 2021. Dr...


CEO Compensation Analysis

Compensation vs Market: Hermann's total compensation ($USD655.13K) is above average for companies of similar size in the German market ($USD404.30K).

Compensation vs Earnings: Hermann's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: B8F's management team is considered experienced (3.2 years average tenure).


Board Members

Experienced Board: B8F's board of directors are not considered experienced ( 0.4 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Biofrontera AG's employee growth, exchange listings and data sources


Key Information

  • Name: Biofrontera AG
  • Ticker: B8F
  • Exchange: XTRA
  • Founded: 1997
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: €60.120m
  • Shares outstanding: 56.72m
  • Website: https://www.biofrontera.com

Number of Employees


Location

  • Biofrontera AG
  • Hemmelrather Weg 201
  • Leverkusen
  • North Rhine-Westphalia
  • 51377
  • Germany

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/05/22 00:00
End of Day Share Price2022/05/20 00:00
Earnings2022/03/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.